Sildenafil for early lung blood-pressure problems in scleroderma
Treatments studied
Part of Skin clinical trials.
This trial tests whether sildenafil can improve early “high pressure in the lung blood vessels” in people with scleroderma. It may help slow worsening breathing and lung blood-vessel disease before it becomes severe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have scleroderma confirmed by specific 2013 classification criteria
- Recent lung-heart measurements show mean lung artery pressure 21–24 (with low left-sided heart filling pressure)
- Your breathing tests are not too reduced (FEV1/FVC above 50%) and lung volumes are mostly preserved or only mildly affected
- Your scan does not show long-term blocked lung blood vessels (chronic thromboembolism)
- You can safely do a 6-minute walk test
- You are able to sign consent and are 18 or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests if sildenafil can help people with severe pulmonary hypertension caused by rheumatic valvular heart disease. It aims to see if the drug improves symptoms and heart function.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This study looks for signs of high blood pressure in the lungs (pulmonary hypertension) in people with scleroderma. It aims to catch it early so it can be treated.
This trial tests whether a special type of stem cells from umbilical cords can help people with scleroderma-related lung disease that is getting worse. You may qualify if your lung function has declined despite current treatments.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Hear when a new Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.